Akums Drugs and Pharmaceuticals Limited Stock Price Today (NSE: AKUMS)
Fundamental Score
Akums Drugs and Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Akums Drugs and Pharmaceuticals Limited share price today is ₹772.00, up +0.83% on NSE/BSE as of 16 September 2026. Akums Drugs and Pharmaceuticals Limited (AKUMS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹11.82K (Cr). The 52-week high for AKUMS share price is ₹796.55 and the 52-week low is ₹409.30. At a P/E ratio of 40.52x, AKUMS is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 8.02% and a debt-to-equity ratio of 0.02.
Akums Drugs and Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Akums Drugs and Pharmaceuticals Limited share price chart: 0.89% return over the past month. 52-week high ₹796.55, 52-week low ₹409.30.
Akums Drugs and Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹759.20 | ₹775.00 | ₹746.40 | ₹772.00 | 2.36L (Cr) | |
| ₹780.25 | ₹792.00 | ₹762.15 | ₹765.65 | 3.45L (Cr) | |
| ₹753.00 | ₹784.40 | ₹740.50 | ₹776.35 | 3.99L (Cr) | |
| ₹741.10 | ₹755.10 | ₹740.35 | ₹749.65 | 2.89L (Cr) | |
| ₹737.00 | ₹769.00 | ₹737.00 | ₹741.10 | 4.34L (Cr) | |
| ₹754.05 | ₹757.75 | ₹733.15 | ₹736.60 | 1.99L (Cr) | |
| ₹765.75 | ₹772.90 | ₹751.50 | ₹754.65 | 1.21L (Cr) | |
| ₹784.40 | ₹785.00 | ₹748.35 | ₹765.75 | 3.39L (Cr) | |
| ₹764.35 | ₹788.00 | ₹760.50 | ₹780.55 | 3.36L (Cr) | |
| ₹778.00 | ₹794.90 | ₹768.20 | ₹770.25 | 7.50L (Cr) |
Akums Drugs and Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹780.50 | ₹796.55 | ₹733.15 | ₹772.00 | -1.09% | |
| ₹666.70 | ₹785.00 | ₹656.50 | ₹776.70 | +16.50% | |
| ₹623.27 | ₹714.70 | ₹620.00 | ₹658.35 | +5.63% | |
| ₹524.50 | ₹639.84 | ₹517.00 | ₹620.19 | +18.24% | |
| ₹550.00 | ₹567.00 | ₹500.05 | ₹524.50 | -4.64% | |
| ₹473.90 | ₹557.00 | ₹473.90 | ₹547.30 | +15.49% | |
| ₹472.00 | ₹515.00 | ₹456.55 | ₹466.10 | -1.25% | |
| ₹445.00 | ₹506.00 | ₹424.20 | ₹488.15 | +9.70% | |
| ₹453.40 | ₹458.00 | ₹409.30 | ₹439.55 | -3.05% | |
| ₹425.95 | ₹480.50 | ₹414.00 | ₹453.40 | +6.44% | |
| ₹463.95 | ₹481.70 | ₹411.40 | ₹425.95 | -8.19% | |
| ₹441.50 | ₹473.45 | ₹437.00 | ₹460.75 | +4.36% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Akums Drugs and Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Akums Drugs and Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AKUMS across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Robust Profit Growth (57.56%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Profit Growth Track Record (15.68% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (5.06x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.55)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹952.52 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Below-Average Return on Equity (8.02%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Premium Valuation Risk (P/E: 40.52x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-55.67% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Akums Drugs and Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Akums Drugs and Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
41.9/100 | ₹772.00₹772 | ₹11819.71₹11819.71 | 40.52Average 40.5 Average | 8.02%Poor 8.02% Poor | 12.58%Average 12.58% Average | 0.02Excellent 0.0 Excellent | 15.68%Excellent 15.68% Excellent | 9.87%Good 9.87% Good | 0.14% | |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9443.00₹9443 | ₹250239.50₹250239.50 | 85.68Average 85.7 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1370.20₹1370 | ₹110691.61₹110691.61 | 32.83Average 32.8 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1672.10₹1672 | ₹96212.63₹96212.63 | 26.13Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.80₹1146 | ₹95674.30₹95674.30 | 29.61Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price250239.50 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110691.61 Cr
Akums Drugs and Pharmaceuticals Limited PE Ratio History
Historical price-to-earnings ratio for AKUMS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹22.60 | ₹453.40 | 20.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Akums Drugs and Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for AKUMS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
13.93%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
57.56%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.87%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
15.68%
Compounded annual net profit growth over 5 years
Akums Drugs and Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AKUMS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Akums Drugs and Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Akums Drugs and Pharmaceuticals Limited (AKUMS) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Akums Drugs and Pharmaceuticals Limited
About AKUMS (Akums Drugs and Pharmaceuticals Limited)
Akums Drugs & Pharmaceuticals Ltd. is a powerhouse within the Indian pharmaceutical landscape, standing as a comprehensive contract development and manufacturing organization (CDMO...). They function as a vital hub, orchestrating the production of a vast portfolio of pharmaceutical and healthcare solutions, spanning from essential medications to sophisticated formulations. The company's expertise extends across diverse therapeutic areas, catering to both acute and chronic conditions with unwavering commitment to quality and innovation. With a strong foothold in the domestic market, Akums also strategically projects its reach globally, solidifying its position as a reliable partner for pharmaceutical companies seeking manufacturing excellence. This unwavering dedication has positioned Akums as a significant contributor to the healthcare industry, enabling the provision of affordable and quality healthcare solutions for diverse demographics. Beyond conventional pharmaceuticals, Akums embraces a holistic approach to well-being, demonstrated by its involvement in the production of ayurvedic medicines, herbal remedies, and nutraceuticals. This reflects an awareness of the growing consumer demand for natural and alternative therapies, with production conducted under rigorous regulatory standards and quality controls. The company's comprehensive product range further incorporates toiletries, derma and cosmetic products, and food supplements, showcasing its diversification and commitment to addressing various aspects of health and personal care. Akums is dedicated to continuously refining its processes and technologies, ensuring the delivery of products that align with the evolving needs of the healthcare industry. Akums Drugs & Pharmaceuticals Ltd. operates a network of state-of-the-art manufacturing facilities adhering to stringent international quality standards, including certifications from WHO-GMP and other reputed regulatory bodies. This infrastructural strength enables the company to deliver a wide range of dosage forms, including tablets, capsules, liquids, injectables, and topical preparations. Moreover, the company offers a comprehensive suite of services encompassing formulation development, analytical testing, and stability studies, positioning it as a complete solution provider for pharmaceutical companies. By fostering collaborations and partnerships, Akums aims to drive advancements in healthcare, enabling access to quality and affordable medicines for populations worldwide.
Company Details
Key Leadership
AKUMS Share Price: Frequently Asked Questions
What is the current share price of Akums Drugs and Pharmaceuticals Limited?
Akums Drugs and Pharmaceuticals Limited (AKUMS) trades at ₹772.00 on NSE and BSE. Market cap ₹11.82K (Cr). Educational data only.
What is the P/E ratio of Akums Drugs and Pharmaceuticals Limited?
Akums Drugs and Pharmaceuticals Limited has a P/E of 40.52x vs industry average 34.89x.
What is the Bull Run score for Akums Drugs and Pharmaceuticals Limited?
Akums Drugs and Pharmaceuticals Limited has a Bull Run score of 41.9/100 based on 25+ financial parameters.
Does Akums Drugs and Pharmaceuticals Limited pay dividends?
Akums Drugs and Pharmaceuticals Limited has a dividend yield of 0.14%. Past dividends don't guarantee future payments.
What is the ROE of Akums Drugs and Pharmaceuticals Limited?
Akums Drugs and Pharmaceuticals Limited has ROE of 8.02%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Akums Drugs and Pharmaceuticals Limited?
Akums Drugs and Pharmaceuticals Limited has debt-to-equity of 0.02.
Is Akums Drugs and Pharmaceuticals Limited a good investment?
Bull Run gives Akums Drugs and Pharmaceuticals Limited a score of 41.9/100. This is not investment advice — consult a SEBI-registered advisor.